Last viewed:
acad
Prices are updated after-hours
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
(0.0% 1d)
(-8.6% 1m)
(-16.3% 1y)
(0.0% 2d)
(-2.3% 3d)
(-0.4% 7d)
(Infinity%
volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,771,456,983
http://www.acadia-pharm.com
Sec
Filling
|
Patents
| 503 employees
(US) ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
nervous system
parkinson
msa
treatment
add to watch list
Paper trade
email alert is off
Press-releases
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Published: 2024-04-17
(Crawled : 23:00)
- biospace.com/
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -1.52%
| O: 0.76%
H: 0.0%
C: 0.0%
neurology
pharmaceuticals
meeting
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-01
(Crawled : 23:00)
- biospace.com/
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -9.03%
| O: 0.54%
H: 0.0%
C: -1.78%
conference
pharmaceuticals
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Published: 2024-03-13
(Crawled : 23:00)
- biospace.com/
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -15.82%
| O: -0.35%
H: 2.16%
C: -1.76%
day
pharmaceuticals
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
Published: 2024-02-29
(Crawled : 15:00)
- biospace.com/
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -29.16%
| O: 2.34%
H: 0.0%
C: -4.36%
conference
health
care
pharmaceuticals
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
Published: 2024-02-27
(Crawled : 23:00)
- biospace.com/
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -35.06%
| O: 0.54%
H: 2.0%
C: 1.23%
year
pharmaceuticals
financial
results
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Published: 2024-02-13
(Crawled : 00:00)
- biospace.com/
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -37.14%
| O: -2.58%
H: 1.29%
C: -1.96%
year
pharmaceuticals
financial
results
Acadia Announces Additions to Executive Team - Jan 31, 2024
Published: 2024-01-31
(Crawled : 10:00)
- biospace.com/
INBX
|
$34.36
-0.26%
-0.26%
220K
|
Health Technology
| -11.43%
| O: -0.36%
H: 0.57%
C: -0.21%
EXEL
|
$22.51
0.09%
0.09%
2.3M
|
Health Technology
| 2.88%
| O: 0.18%
H: 0.55%
C: -0.78%
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -37.31%
| O: -0.71%
H: 0.71%
C: -2.74%
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Published: 2023-12-21
(Crawled : 00:00)
- biospace.com/
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -42.1%
| O: 1.76%
H: 1.23%
C: -0.14%
conference
pharmaceuticals
Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Assesses DelveInsight | Key Players in the Market - Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo
Published: 2023-12-19
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
| -3.41%
| O: -0.39%
H: 1.49%
C: 0.32%
SUPN
|
$29.43
1.94%
1.9%
360K
|
Health Technology
| 4.59%
| O: -0.11%
H: 0.82%
C: -2.31%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
| -4.87%
| O: 0.21%
H: 0.0%
C: 0.0%
AXSM
|
$67.91
3.33%
3.22%
890K
|
Health Technology
| -8.06%
| O: -0.46%
H: 0.0%
C: -4.03%
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -44.18%
| O: -0.17%
H: 0.76%
C: -3.42%
therapeutics
growth
study
market
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Published: 2023-12-18
(Crawled : 11:00)
- prnewswire.com
ACAD
|
$16.82
-1.47%
-1.49%
3.5M
|
Health Technology
| -41.15%
| O: -0.28%
H: 3.05%
C: 1.82%
trial
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001415889-24-010604
4
2024-04-09
2024-04-05
Sell
M
34666
138666
0001415889-24-010604
4
2024-04-09
2024-04-05
Sell
M
17333
34667
0001415889-24-010604
4
2024-04-09
2024-04-08
Sell
S
17716
144267
0001415889-24-010604
4
2024-04-09
2024-04-08
Sell
S
8858
161983
0001415889-24-010604
4
2024-04-09
2024-04-05
Buy
M
34666
170841
0001415889-24-010604
4
2024-04-09
2024-04-05
Buy
M
17333
136175
0001415889-24-010603
4
2024-04-09
2024-04-05
Sell
M
5024
10048
0001415889-24-010603
4
2024-04-09
2024-04-08
Sell
S
2568
38796
0001415889-24-010603
4
2024-04-09
2024-04-05
Buy
M
5024
41364
0001415889-24-010602
4
2024-04-09
2024-04-07
Sell
M
1489
0
0001415889-24-010602
4
2024-04-09
2024-04-05
Sell
M
2010
4020
0001415889-24-010602
4
2024-04-09
2024-04-08
Sell
S
762
13100
0001415889-24-010602
4
2024-04-09
2024-04-08
Sell
S
1028
13862
0001415889-24-010602
4
2024-04-09
2024-04-07
Buy
M
1489
14890
0001415889-24-010602
4
2024-04-09
2024-04-05
Buy
M
2010
13401
0001415889-24-010601
4
2024-04-09
2024-04-05
Sell
M
5275
10551
0001415889-24-010601
4
2024-04-09
2024-04-08
Sell
S
2716
28742
0001415889-24-010601
4
2024-04-09
2024-04-05
Buy
M
5275
31458